Free Design Audit Available - Click Here for Details

FDA clears DermaSensor AI-powered skin cancer detection device

DermaSensor announced today that the FDA cleared its real-time, non-invasive, AI-powered skin cancer evaluation system.

Miami-based DermaSensor develops a handheld device that uses ESS, a form of optical spectroscopy. It takes noninvasive samples of tissue, capturing cellular-level information. The technology uses hundreds of wavelengths of light in a manner similar to how sonar uses sound.

DermaSensor says physicians can use its AI-powered spectroscopy technology to non-invasively evaluate lesions. They can look at cellular and subcellular characteristics of a lesion in question for skin cancer. The wireless device then provides an immediate, objective result using an FDA-cleared algorithm.

Sign up for Blog Updates